Home » Stocks » NWBO

Northwest Biotherapeutics, Inc. (NWBO)

Stock Price: $1.47 USD -0.03 (-1.70%)
Updated Feb 25, 2021 3:04 PM EST - Market open
Market Cap 1.17B
Revenue (ttm) 1.69M
Net Income (ttm) -242.65M
Shares Out 747.75M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $1.47
Previous Close $1.50
Change ($) -0.03
Change (%) -1.70%
Day's Open 1.52
Day's Range 1.43 - 1.58
Day's Volume 1,808,022
52-Week Range 0.141 - 2.51

News

Hide News
Seeking Alpha - 2 months ago

NWBO has run an 18-year long trial in GBM, one of the deadliest of cancers. It has been mired in controversies, and it has no cash.

The Motley Fool - 3 months ago

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Other stocks mentioned: NVCR
Seeking Alpha - 4 months ago

With Data Lock just announced, Top Line Date is imminent.

About NWBO

Northwest Biotherapeutics, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L that is in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, which is in Phase I/II clinical trials to treat various inoperable solid tumor cancers. The company was foun... [Read more...]

Industry
Biotechnology
Founded
1996
CEO
Linda Powers
Employees
17
Stock Exchange
OTCMKTS
Ticker Symbol
NWBO
Full Company Profile

Financial Performance

In 2019, NWBO's revenue was $2.41 million, an increase of 484.95% compared to the previous year's $412,000. Losses were -$20.30 million, -43.30% less than in 2018.

Financial Statements